150 related articles for article (PubMed ID: 23527324)
21. Imatinib attenuates myocardial fibrosis in association with inhibition of the PDGFRα activity.
Ma LK; Li Q; He LF; Hua JS; Zhou JL; Yu H; Feng KF; Chen HW; Hu H; Wang L
Arq Bras Cardiol; 2012 Dec; 99(6):1082-91. PubMed ID: 23184075
[TBL] [Abstract][Full Text] [Related]
22. PDGF receptor and its antagonists: role in treatment of PAH.
Grimminger F; Schermuly RT
Adv Exp Med Biol; 2010; 661():435-46. PubMed ID: 20204747
[TBL] [Abstract][Full Text] [Related]
23. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
Heinrich MC; McArthur GA; Demetri GD; Joensuu H; Bono P; Herrmann R; Hirte H; Cresta S; Koslin DB; Corless CL; Dirnhofer S; van Oosterom AT; Nikolova Z; Dimitrijevic S; Fletcher JA
J Clin Oncol; 2006 Mar; 24(7):1195-203. PubMed ID: 16505440
[TBL] [Abstract][Full Text] [Related]
24. Delivery of imatinib-incorporated nanoparticles into lungs suppresses the development of monocrotaline-induced pulmonary arterial hypertension.
Akagi S; Nakamura K; Miura D; Saito Y; Matsubara H; Ogawa A; Matoba T; Egashira K; Ito H
Int Heart J; 2015 May; 56(3):354-9. PubMed ID: 25902888
[TBL] [Abstract][Full Text] [Related]
25. Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension.
ten Freyhaus H; Dumitrescu D; Bovenschulte H; Erdmann E; Rosenkranz S
Clin Res Cardiol; 2009 Apr; 98(4):265-7. PubMed ID: 19219392
[No Abstract] [Full Text] [Related]
26. Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma.
Sugiura H; Fujiwara Y; Ando M; Kawai A; Ogose A; Ozaki T; Yokoyama R; Hiruma T; Ishii T; Morioka H; Mugishima H
J Orthop Sci; 2010 Sep; 15(5):654-60. PubMed ID: 20953927
[TBL] [Abstract][Full Text] [Related]
27. Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations.
Cristofanilli M; Morandi P; Krishnamurthy S; Reuben JM; Lee BN; Francis D; Booser DJ; Green MC; Arun BK; Pusztai L; Lopez A; Islam R; Valero V; Hortobagyi GN
Ann Oncol; 2008 Oct; 19(10):1713-9. PubMed ID: 18515258
[TBL] [Abstract][Full Text] [Related]
28. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.
Droogendijk HJ; Kluin-Nelemans HJ; van Doormaal JJ; Oranje AP; van de Loosdrecht AA; van Daele PL
Cancer; 2006 Jul; 107(2):345-51. PubMed ID: 16779792
[TBL] [Abstract][Full Text] [Related]
29. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
McGary EC; Onn A; Mills L; Heimberger A; Eton O; Thomas GW; Shtivelband M; Bar-Eli M
J Invest Dermatol; 2004 Feb; 122(2):400-5. PubMed ID: 15009722
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.
Huh WK; Sill MW; Darcy KM; Elias KM; Hoffman JS; Boggess JF; Alvarez RD; Long HJ; O'Malley DM; Birrer MJ
Gynecol Oncol; 2010 May; 117(2):248-54. PubMed ID: 20189232
[TBL] [Abstract][Full Text] [Related]
31. Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression.
Ciuclan L; Hussey MJ; Burton V; Good R; Duggan N; Beach S; Jones P; Fox R; Clay I; Bonneau O; Konstantinova I; Pearce A; Rowlands DJ; Jarai G; Westwick J; MacLean MR; Thomas M
Am J Respir Crit Care Med; 2013 Jan; 187(1):78-89. PubMed ID: 23087024
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
[TBL] [Abstract][Full Text] [Related]
33. Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib.
Kinsella P; Howley R; Doolan P; Clarke C; Madden SF; Clynes M; Farrell M; Amberger-Murphy V
Exp Cell Res; 2012 Mar; 318(5):641-52. PubMed ID: 22285130
[TBL] [Abstract][Full Text] [Related]
34. Platelet-derived growth factor receptor-tyrosine kinase inhibitor, imatinib, is effective for treating pulmonary hypertension induced by pulmonary tumor thrombotic microangiopathy.
Minatsuki S; Miura I; Yao A; Abe H; Muraoka H; Tanaka M; Imamura T; Inaba T; Maki H; Hatano M; Kinugawa K; Yao T; Fukayama M; Nagai R; Komuro I
Int Heart J; 2015; 56(2):245-8. PubMed ID: 25740390
[TBL] [Abstract][Full Text] [Related]
35. Imatinib mesylate inhibits cell growth of malignant peripheral nerve sheath tumors in vitro and in vivo through suppression of PDGFR-β.
Ohishi J; Aoki M; Nabeshima K; Suzumiya J; Takeuchi T; Ogose A; Hakozaki M; Yamashita Y; Iwasaki H
BMC Cancer; 2013 May; 13():224. PubMed ID: 23642185
[TBL] [Abstract][Full Text] [Related]
36. [Experience with imatinib to treat pulmonary arterial hypertension].
García Hernández FJ; Castillo Palma MJ; González León R; Garrido Rasco R; Ocaña Medina C; Sánchez Román J
Arch Bronconeumol; 2008 Dec; 44(12):689-91. PubMed ID: 19091239
[TBL] [Abstract][Full Text] [Related]
37. Imatinib mesylate attenuates myocardial remodeling through inhibition of platelet-derived growth factor and transforming growth factor activation in a rat model of hypertension.
Jang SW; Ihm SH; Choo EH; Kim OR; Chang K; Park CS; Kim HY; Seung KB
Hypertension; 2014 Jun; 63(6):1228-34. PubMed ID: 24591339
[TBL] [Abstract][Full Text] [Related]
38. Impact of lowering pulmonary vascular resistance on right and left ventricular deformation in pulmonary arterial hypertension.
Querejeta Roca G; Campbell P; Claggett B; Vazir A; Quinn D; Solomon SD; Shah AM
Eur J Heart Fail; 2015 Jan; 17(1):63-73. PubMed ID: 25367310
[TBL] [Abstract][Full Text] [Related]
39. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
Wyman K; Atkins MB; Prieto V; Eton O; McDermott DF; Hubbard F; Byrnes C; Sanders K; Sosman JA
Cancer; 2006 May; 106(9):2005-11. PubMed ID: 16565971
[TBL] [Abstract][Full Text] [Related]
40. Platelet-derived growth factor inhibition--a new treatment of pulmonary hypertension in congenital diaphragmatic hernia?
Frenckner B; Broomé M; Lindström M; Radell P
J Pediatr Surg; 2008 Oct; 43(10):1928-31. PubMed ID: 18926235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
